المؤلفون: T. Yu. Yafoshkina, D. B. Florinskiy, A. E. Rudneva, P. A. Levin, P. A. Zharkov, Т. Ю. Яфошкина, Д. Б. Флоринский, А. Е. Руднева, П. А. Левин, П. А. Жарков

المساهمون: The study was performed without external funding., Исследование проведено без спонсорской поддержки.

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 11, № 2 (2024); 21-27 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 11, № 2 (2024); 21-27 ; 2413-5496 ; 2311-1267

مصطلحات موضوعية: асимптоматический тромбоз у детей, post-thrombotic syndrome in children, post-thrombotic syndrome following asymptomatic thrombosis, long-term complications of deep vein thrombosis, incidental thrombosis in child, посттромботический синдром у детей, посттромботический синдром после асимптоматических тромбозов, осложнения тромбоза глубоких вен

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/1036/925; O’Brien S.H., Stanek J.R., Witmer C.M., Raffi ni L. The Continued Rise of Venous Thromboembolism Across US Children’s Hospitals. Pediatrics. 2022;149(3):e2021054649. doi:10.1542/peds.2021-054649.; Sol J.J., Knoester H., de Neef M., Smets A.M.J.B., Betlem A., van Ommen C.H. Chronic Complications After Femoral Central Venous Catheter-related Thrombosis in Critically Ill Children. J Pediatr Hematol Oncol. 2015;37(6):462–7. doi:10.1097/MPH.0000000000000370.; https://www.uptodate.com/contents/venous-thrombosis-andthromboembolism-vte-in-children-risk-factors-clinicalmanifestations-and-diagnosis.; Monagle P., Chan A.K.C., Goldenberg N.A., Ichord R.N., Journeycake J.M., Nowak-Göttl U., Vesely S.K. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S–e801S. doi:10.1378/chest.11-2308. Erratum in: Chest. 2014;146(6):1694. Dosage error in article text. Erratum in: Chest. 2014;146(5):1422. PMID: 22315277.; Monagle P., Cuello C.A., Augustine C., Bonduel M., Brandão L.R., Capman T., Chan A.K.C., Hanson S., Male C., Meerpohl J., Newall F., O’Brien S.H., Raffi ni L., van Ommen H., Wiernikowski J., Williams S., Bhatt M., Riva J.J., Roldan Y., Schwab N., Mustafa R.A., Vesely S.K. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018;2(22):3292–3316. doi:10.1182/bloodadvances.2018024786.; Жарков П.A. Антитромботическая терапия и профилактика тромбозов глубоких вен у детей с гемобластозами и синдромами костномозговой недостаточности. Автореф. дис. … д-ра мед. наук. М., 2019. 52 с.; Jones S., Monagle P., Newall F. Do asymptomatic clots in children matter? Thromb Res. 2020;189:24–34. doi:10.1016/j.thromres.2020.02.013.; Яфошкина Т.Ю., Жарков П.А. Посттромботический синдром у детей (обзор литературы). Российский журнал детской гематологии и онкологии (РЖДГиО). 2022;9(1):45–51. doi:10.21682/2311-1267-2022-9-1-45-51.; Manco-Johnson M.J., Knapp-Clevenger R., Miller B.I., Hays T. Post-thrombotic syndrome (PTS) in children: validation of a new pediatric outcome instrument and results in a comprehensive cohort of children with extremity deep vein thrombosis (DVT). Blood. 2003;102:553A–553A abstract. ISI.; Kuhle S., Koloshuk B., Marzinotto V., Bauman M., Massicotte P., Andrew M., Chan A., Abdolell M., Mitchell L. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res. 2003;111(4–5):227–33. doi:10.1016/j.thromres.2003.09.008. PMID: 14693168.; Avila M.L., Feldman B.M., Pullenayegum E., Lumia C., Montoya M.I., Vincelli J. Post-thrombotic syndrome in children: Measurement properties of CAPTSure, a new diagnostic tool. Res Pract Thromb Haemost. 2019;3(4):652–7. doi:10.1002/rth2.12251. PMID: 31624784.; Avila L., Amiri N., De R., Vincelli J., Pullenayegum E., Williams S., Brandão L.R. Characteristics of upper- and lower-extremity deep vein thrombosis and predictors of postthrombotic syndrome in children. Blood Adv. 2021;5(19):3737–47. doi:10.1182/bloodadvances.2021004727.; Клинические рекомендации «Острый лимфобластный лейкоз». М., 2020.; Kuhle S., Spavor M., Massicotte P., Halton J., Cherrick I., Dix D., Mahoney D., Bauman M., Desai S., Mitchell L.G. Prevalence of postthrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost. 2008;6(4):589–94. doi:10.1111/j.1538-7836.2008.02901.x.; Avila M.L., Duan L., Cipolla A., Kim A., Kahr W.H.A., Williams S., Brandão L.R. Postthrombotic syndrome following upper extremity deep vein thrombosis in children. Blood. 2014;124(7):1166–73. doi:10.1182/blood-2014-04-570531.; Engel E.R., Nguyen A.T.H., Amankwah E.K., Albisetti M., Brandão L.R., Goldenberg N.A., Betensky M. Predictors of postthrombotic syndrome in pediatric thrombosis: A systematic review and meta-analysis of the literature. J Thromb Haemost. 2020;18(10):2601–12. doi:10.1111/jth.14984.; Жарков П.А., Шифрин Ю.А., Новичкова Г.А. Эффективность антитромботической терапии тромбозов глубоких вен у детей с заболеваниями крови. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019;18(1):34–42. doi:10.24287/1726-1708-2019-18-1-34-42.; Kumar R., Rodriguez V., Matsumoto J.M., Khan S.P., Weaver A.L., McBane R.D. Health-related quality of life in children and young adults with post-thrombotic syndrome: results from a cross-sectional study. Pediatr Blood Cancer. 2014;61(3):546–51. doi:10.1002/pbc.24840. PMID: 24347376.; Avila L., Betensky M., Cohen C., Ahuja S., Goldenberg N., Zia A. Clinical care of pediatric patients with or at risk of postthrombotic syndrome: guidance from the ISTH SSC Subcommittee on pediatric and neonatal thrombosis and hemostasis. J Thromb Haemost. 2024;22(2):365–78. doi:10.1016/j.jtha.2023.10.012.; https://journal.nodgo.org/jour/article/view/1036

الاتاحة: https://journal.nodgo.org/jour/article/view/1036
https://doi.org/10.21682/2311-1267-2024-11-2-21-27

المؤلفون: T. Yu. Yafoshkina, Yu. A. Shifrin, D. V. Fedorova, D. B. Florinskiy, D. A. Evstratov, P. A. Zharkov, Т. Ю. Яфошкина, Ю. А. Шифрин, Д. В. Федорова, Д. Б. Флоринский, Д. А. Евстратов, П. А. Жарков

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 10, № 1 (2023); 33-40 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 10, № 1 (2023); 33-40 ; 2413-5496 ; 2311-1267

مصطلحات موضوعية: новые пероральные антикоагулянты, thrombosis therapy, thrombosis in children, anticoagulants, new oral anticoagulants, терапия тромбозов, тромбозы у детей, антикоагулянты

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/919/813; Raffini L., Huang Y.S., Witmer C., Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001–8. doi:10.1542/peds.2009-0768.; Федеральные клинические рекомендации по диагностике, профилактике и лечению тромбозов у детей и подростков. М., 2015.; [Электронный ресурс]. URL: https://www.uptodate.com/contents/venous-thrombosis-and-thromboembolism-vte-in-children-riskfactors-clinical-manifestations-and-diagnosis. (Дата обращения: 14.09.2022).; De Crem N., Peerlinck K., Vanassche T., Vanheule K., Debaveye B., Middeldorp S., Verhamme P., Peetermans M. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res. 2015;136(4):749–53. doi:10.1016/j.thromres.2015.07.030.; Kaatz S., Ahmad D., Spyropoulos A.C., Schulman S.; Subcommittee on Control of Anticoagulation. Definition of clinically relevant nonmajor bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–26. doi:10.1111/jth.13140.; [Электронный ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=073cdf44-10f6-4fa4-ab24-a5727d8c90f5. (Дата обращения: 17.01.2023).; Halton J., Brandão L.R., Luciani M., Bomgaars L., Chalmers E., Mitchell L.G., Nurmeev I., Sharathkumar A., Svirin P., Gorbatikov K., Tartakovsky I., Simetzberger M., Huang F., Sun Z., Kreuzer J., Gropper S., Reilly P., Brueckmann M., Albisetti M.; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021;8(1):e22–33. doi:10.1016/S2352-3026(20)30368-9.; Male C., Lensing A.W.A., Palumbo J.S., Kumar R., Nurmeev I., Hege K., Bonnet D., Connor P., Hooimeijer H.L., Torres M., Chan A.K.C., Kenet G., Holzhauer S., Santamaría A., Amedro P., Chalmers E., Simioni P., Bhat R.V., Yee D.L., Lvova O., BeyerWestendorf J., Biss T.T., Martinelli I., Saracco P., Peters M., Kállay K., Gauger C.A., Massicotte M.P., Young G., Pap A.F., Majumder M., Smith W.T., Heubach J.F., Berkowitz S.D., Thelen K., Kubitza D., Crowther M., Prins M.H., Monagle P.; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18–27. doi:10.1016/S2352-3026(19)30219-4.; Bryk A.H., Piróg M., Plens K., Undas A. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. Vascul Pharmacol. 2016;87:242–7. doi:10.1016/j.vph.2016.11.003.; Bannow B.S. Management of heavy menstrual bleeding on anticoagulation. Hematology Am Soc Hematol Educ Program. 2020;2020(1):533–7. doi:10.1182/hematology.2020000138.; Limperger V., Torge A., Kiesau B., Langer F., Kenet G., Mesters R., Juhl D., Stoll M., Shneyder M., Kowalski D., Bajorat T., Rocke A., Kuta P., Lasarow L., Spengler D., Junker R., Nowak-Göttl U. Validation of a predictive model for identifying an increased risk for recurrence in adolescents and young adults with a first provoked thromboembolism. Blood Cells Mol Dis. 2022;94:102651. doi:10.1016/j.bcmd.2022.102651.; Brandão L.R., Albisetti M., Halton J., Bomgaars L., Chalmers E., Mitchell L.G., Nurmeev I., Svirin P., Kuhn T., Zapletal O., Tartakovsky I., Simetzberger M., Huang F., Sun Z., Kreuzer J., Gropper S., Brueckmann M., Luciani M.; DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020;135(7):491–504. doi:10.1182/blood.2019000998.; Pinchinat A., Otero N., Mahanti H., Morris E., Brudnicki A., Friedman D., Li S., Levendoglu-Tugal O., Cairo M.S.; A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents. Blood. 2019;134(Suppl. 1):2443. doi:10.1182/blood-2019-130468.; O’Brien S., Rodriguez V., Lew G., Newburger J., Schultz C., Orgel E., Derr K., Ranalli M., Esbenshade A., Hochberg J., Kang H., Dinikina Y., Crevar C., Donovan M., Dyme J., Favatella N., Mitchell L. PREVAPIX-ALL: Phase 3 Study of the Safety and Efficacy of Apixaban for Thromboprophylaxis versus Standard of Care in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia or Lymphoma (ALL/LL). [Электронный ресурс]. URL: https://abstracts.isth.org/abstract/prevapix-all-phase-3-study-of-the-safety-and-efficacy-ofapixaban-for-thromboprophylaxis-versus-standard-of-care-in-newlydiagnosed-pediatric-acute-lymphoblastic-leukemia-or-lymphoma-all-ll/. Accessed January 23, 2023.; McCrindle B.W., Michelson A.D., Van Bergen A.H., Horowitz E.S., Sandoval J.P., Justino H., Harris K.C., Jefferies J.L., Pina L.M., Peluso C., Nessel K., Lu W., Li J.S.; UNIVERSE Study Investigators. Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study. J Am Heart Assoc. 2021;10(22):e021765. doi:10.1161/JAHA.120.021765.; Nowak-Göttl U., Junker R., Kreuz W., von Eckardstein A., Kosch A., Nohe N., Schobess R., Ehrenforth S.; Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97(4):858–62. doi:10.1182/blood.v97.4.858.; Goldenberg N.A., Pounder E., Knapp-Clevenger R., Manco-Johnson M.J. Validation of upper extremity post-thrombotic syndrome outcome measurement in children. J. Pediatr. 2010;157(5):852–5. doi:10.1002/rth2.12251.; Goldenberg N.A., Donadini M.P., Kahn S.R., Crowther M., Kenet G., Nowak-Göttl U., Manco-Johnson M.J. Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica. 2010;95(11):1952–9. doi:10.3324/haematol.2010.026989.; Avila M.L., Feldman B.M., Pullenayegum E., Lumia C., Montoya M.I., Vincelli J., Williams S., Brandão L.R. Post-thrombotic syndrome in children: Measurement properties of CAPTSure, a new diagnostic tool. Res Pract Thromb Haemost. 2019;3(4):652–7. doi:10.1002/rth2.12251.; https://journal.nodgo.org/jour/article/view/919

الاتاحة: https://journal.nodgo.org/jour/article/view/919
https://doi.org/10.21682/2311-1267-2023-10-1-33-40

المؤلفون: D. B. Florinskiy, P. A. Zharkov, Д. Б. Флоринский, П. А. Жарков

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 7, № 4 (2020); 71-76 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 7, № 4 (2020); 71-76 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2020-7-4

مصطلحات موضوعية: профилактика, factor concentrates, cryoprecipitate, fibrinogen, therapy, prevention, концентраты факторов, криопреципитат, фибриноген, терапия

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/670/614; Mannucci P.M., Duga S., Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243-52. PMID: 15138162.; Mumford A.D., Ackroyd S., Alikhan R., Bowles L., Chowdary P., Grainger J., Mainwaring J., Mathias M., O’Connell N. BCSH Committee Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014;167:304-26. PMID: 25100430.; Caudill J.S., Nichols W.L., Plumhoff E.A., Schulte S.L., Winters J.L., Gastineau D.A., Rodriguez V. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion 2009;49(4):765-70. PMID: 19192257.; Зозуля Н. И., Свирин П . В. Диагностика и лечение редких коагулопатий: наследственный дефицит факторов свертывания крови II, VII, X. Национальные клинические рекомендации, 2014 г.; Tabibian S., Yavar S., Shams M., Safa M., Gholami M.S., Heydari F., Ahmadi A., Rashidpanah J., Dorgalaleh A. A comprehensive overview of coagulation factor V and congenital factor V deficiency. Semin Thromb Hemost 2019;45(5):523-43. PMID: 31121608.; Stirling Y., Woolf L., North W.R., Seghatchian M.J., Meade T.W. Haemostasis in normal pregnancy. Thromb Haemost 1984;52:176-82. PMID: 6084322.; Mariani G., Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009;35(4):400-6. PMID: 20391303.; Woehrle D., Martinez M., Bolliger D. Hereditary heterozygous factor VII deficiency in patients undergoing surgery: clinical relevance. Anaesthesist 2016;65(10):746-54. PMID: 27586406.; Vorstand der Bundesarztekammer auf Empfehlung des Wissenschaftlichen Beirats. Querschnittsleitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, 2014; 4. uberarbeitete und aktualisierte Auflage.; van Geffen M., Mathijssen N.C.J., Holme P.A., Britta A.P., van Gorkom L., van Kraaij M.G.J., Masereeuw R., Peyvandi F., van Heerde W.L. Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. Thromb Res 2013;132(2):256-62. PMID: 23834817.; Государственный реестр лекарственных средств. Режим доступа: [Электронный ресурс]. URL: http://grls.rosminzdrav.ru/Default.aspx.; Livnat T., Tamarin I., Mor Y., Winckler H., Horowitz Z., Korianski Y., Bar-Zakay B., Seligsohn U., Salomon O. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009;102:487-92. PMID: 19718468.; Dorgalaleh A., Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016;30(6):461-75. PMID: 27344554.; Lusher J., Pipe S.W., Alexander S., Nugent D. Prophylactic therapy with Fibrogammin® P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010;16:316-21. PMID: 20017752.; Karaman S., Akkaya E., Genc S., Bilgili F., Kendirci A.S., Tugcu D., Unuvar A., Karakas Z., Demirkol D., Bayramoglu Z., Omer B. Congenital Factor XIII Deficiency With the Presence of Inhibitor: A Case Study. J Pediatr Hematol Oncol 2019. doi:10.1097/MPH.0000000000001671.; Key N.S., Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007;370(9585):439-48. PMID: 17679021.; Spreafico M., Peyvandi F. Combined Factor V and Factor VIII Deficiency. Semin Thromb Hemost 2009;35(4):390-9. PMID: 19598067.; Brenner B., Kuperman A.A., Watzka M., Oldenburg J. Vitamin K-dependent coagulation factors deficiency. Semin Thromb Hemost 2009 Jun;35(4):439-46. PMID: 19598072.; McMahon M.J., James A.H. Combined deficiency of factors II, VII, IX, and X (Borgschulte-Grigsby deficiency) in pregnancy. Obstet Gynecol 2001;97:808-9. PMID: 11336760.; Peyvandi F., Palla R., Menegatti M., Siboni S.M., Halimeh S., Faeser B., Pergantou H., Platokouki H., Giangrande P., Peerlinck K., Celkan T., Ozdemir N., Bidlingmaier C., Ingerslev J., Giansily-Blaizot M., Schved J.F., Gilmore R., Gadisseur A., Benedik-Dolnicar M., Kitanovski L., Mikovic D., Musallam K.M., Rosendaal F.R.; European Network of Rare Bleeding Disorders Group. Coagulation Factor Activity and Clinical Bleeding Severity in Rare Bleeding Disorders: Results From the European Network of Rare Bleeding Disorders J Thromb Haemost 2012;10(4):615-21. PMID: 22321862.; https://journal.nodgo.org/jour/article/view/670

الاتاحة: https://journal.nodgo.org/jour/article/view/670
https://doi.org/10.21682/2311-1267-2020-7-4-71-76

المؤلفون: P. A. Zharkov, D. B. Florinskiy, O. V. Aleynikova, G. A. Novichkovа

المصدر: Pediatric Hematology/Oncology and Immunopathology. 22:78-83

مصطلحات موضوعية: Oncology, Immunology, Pediatrics, Perinatology and Child Health, Immunology and Allergy, Hematology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::a9f3d5bbbbe5c9d9cc4b6379861d596b
https://doi.org/10.24287/1726-1708-2023-22-1-78-83

المؤلفون: D. B. Florinskiy, P. A. Zharkov, Д. Б. Флоринский, П. А. Жарков

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 7, № 3 (2020); 54-63 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 7, № 3 (2020); 54-63 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2020-7-3

مصطلحات موضوعية: фибриноген, FXII, factor concentrates, cryoprecipitate, fibrinogen, концентраты факторов, криопреципитат

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/625/571; Mannucci P.M., Duga S., Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243–52. PMID: 15138162.; Palla R., Peyvandi F., Shapiro A.D. Rare bleeding disorders: diagnosis and treatment. Blood 2015;125(13):2052‒61. PMID: 25712993.; de Moerloose P., Casini A., Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39:585–95. PMID: 23852822.; Lak M., Keihani M., Elahi F., Peyvandi F., Mannucci P.M. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999;107(1):204–6. PMID: 10520042.; Mackie I.J., Kitchen S., Machin S.J., Lowe G.D. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on Fibrinogen Assays. Br J Haematol 2003;121(3):396‒404. PMID: 12716361.; Lancellotti S., De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost 2009;35(4):367‒81. PMID: 19598065.; Tabibian S., Shiravand Y., Shams M., Safa M., Gholami M.S., Heydari F., Ahmadi A., Rashidpanah J., Dorgalaleh A. A comprehensive overview of coagulation factor V and congenital factor V deficiency. Semin Thromb Hemost 2019;45(5):523‒43. PMID: 31121608.; Mariani G., Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009;35(4):400‒6. PMID: 20391303.; Girolami A., Berti de Marinis G., Bertozzi I., Peroni E., Tasinato V., Lombardi A.M. Discrepant ratios of arterial vs. venous thrombosis in hemophilias A and B as compared to FVII deficiency. Eur J Haematol 2013;91(2):152‒6. PMID: 23621110.; Wojciechowski V.V., Calina D., Tsarouhas K. A guide to acquired vitamin K coagulophathy diagnosis and treatment: the Russian perspective. Daru 2017;25(1):10. PMID: 28416008.; Menegatti M., Peyvandi F. Factor X Deficiency. Semin Thromb Hemost 2009;35(4):407‒15. PMID: 19598069.; Duga S., Salomon O. Factor XI deficiency. Semin Thromb Hemost 2009;35(4):416‒25. PMID: 19598070.; Dorgalaleh A., Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016;30(6):461‒75. PMID: 27344554.; Inbal A., Muszbek L. Coagulation factor deficiencies and pregnancy loss. Semin Thromb Hemost 2003;29(2):171–4. PMID: 12709920.; Kohler H., Ichinose A., Seitz R., Ariens R., Muszbek L. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011;9(7):1404–6. PMID: 22946956.; Spreafico M., Peyvandi F. Combined factor V and factor VIII deficiency. Semin Thromb Hemost 2009;35(4):390‒9. PMID: 19598067.; Brenner B., Kuperman A.A., Watzka M., Oldenburg J. Vitamin K-dependent coagulation factors deficiency. Semin Thromb Hemost 2009;35(4):439‒46. PMID: 19598072.; Boneh A., Bar-Ziv J. Hereditary deficiency of vitamin K dependent coagulation factors with skeletal abnormalities. Am J Med Genet 1996;65:241–3. PMID: 9240751.; Ratnoff O.D., Colopy J.E. A familial hemorrhagic trait associated with a deficiency of a clot‐promoting fraction of plasma. J Clin Invest 1955;34:602–13. PMID: 14367514.; Stavrou E., Schmaier A.H. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010;125(3):210–5. PMID: 20022081.; Stavrou E.X., Fang C., Bane K.L., Long A.T., Naudin C., Kucukal E., Gandhi A., Brett-Morris A., Mumaw M.M., Izadmehr S., Merkulova A., Reynolds C.C., Alhalabi O., Nayak L., Yu W.-M., Qu C.-K., Meyerson H.J., Dubyak G.R., Gurkan U.A., Nieman M.T., Gupta A.S., Renné T., Schmaier A.H. Factor XII and uPAR upregulate neutrophil functions to influence wound healing. J Clin Invest 2018;128:944–59. PMID: 29376892.; Colman R.W., Schmaier A.H. Contact activation: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997;90:3819–43. PMID: 9354649.; Lämmle B., Wuillemin W.A., Huber I., Krauskopf M., Zürcher C., Pflugshaupt R., Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency ‒ a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991;65(2):117‒21. PMID: 1905067.; Yau J.W., Stafford A.R., Liao P., Fredenburgh J.C., Roberts R., Weitz J.I. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 2011;118(25):6667–74. PMID: 21937693.; Renné T., Pozgajová M., Grüner S., Schuh K., Pauer H.-U., Burfeind P., Gailani D., Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:271–81. PMID: 16009717.; Merkulov S., Zhang W.-M., Komar A.A., Schmaier A.H., Barnes E., Zhou Y., Lu X., Iwaki T., Castellino F.J., Luo G., McCrae K.R. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008;111:1274–81. PMID: 18000168.; Revenko A.S., Gao D., Crosby J.R., Bhattacharjee G., Zhao C., May C., Gailani D., Monia B.P., MacLeod A.R. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011;118(19):5302–11. PMID: 21821705.; Xu Y., Cai T.Q., Castriota G., Zhou Y., Hoos L., Jochnowitz N., Loewrigkeit C., Cook J.A., Wickham A., Metzger J.M., Ogletree M.L., Seiffert D.A., Chen Z. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost 2014;111(4):694‒704. PMID: 24336918.; Peyvandi F., Palla R., Menegatti M., Siboni S.M., Halimeh S., Faeser B., Pergantou H., Platokouki H., Giangrande P., Peerlinck K., Celkan T., Ozdemir N., Bidlingmaier C., Ingerslev J., Giansily-Blaizot M., Schved J.F., Gilmore R., Gadisseur A., Benedik-Dolničar M., Kitanovski L., Mikovic D., Musallam K.M., Rosendaal F.R.; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012;10(4):615‒21. PMID: 22321862.; https://journal.nodgo.org/jour/article/view/625

الاتاحة: https://journal.nodgo.org/jour/article/view/625
https://doi.org/10.21682/2311-1267-2020-7-3-54-63